SCHEMBL1003605

SCHEMBL1003605

CC(C)(Cc1ccccc1)OC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.49
CYP3A4 P08684 4/20 0.49
CYP2C19 P33261 3/20 0.49
CYP2C9 P11712 2/20 0.49
ALDH1A1 P00352 2/20 0.49
HIF1A Q16665 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SLC6A2 P23975 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
MMP8 P22894 3/20 0.45
CYP2D6 P10635 2/20 0.45
CYP1A2 P05177 2/20 0.45
NFKB1 P19838 1/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
LMNA P02545 2/20 0.44
PMP22 Q01453 1/20 0.44
NLRP3 Q96P20 1/20 0.44
TRPA1 O75762 1/20 0.43
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1003604 0.88 CTSK (0.49) CTSKCYP3A4CYP2C19CYP2C9ALDH1A1
SCHEMBL111212 0.86 ALDH1A1 (0.50) CTSKCYP3A4CYP2C19CYP2C9ALDH1A1
SCHEMBL7816238 0.85 CTSK (0.45) CTSKCYP3A4CYP2C19CYP2C9ALDH1A1
SCHEMBL7288405 0.85 CTSK (0.47) CTSKCYP3A4CYP2C19CYP2C9ALDH1A1
SCHEMBL3656311 0.85 SMN1; SMN2 (0.48) CTSKCYP3A4CYP2C19CYP2C9ALDH1A1
SCHEMBL3248705 0.84 CYP3A4 (0.54) CTSKCYP3A4CYP2C19CYP2C9ALDH1A1
SCHEMBL3833989 0.83 TSHR (0.51) CTSKCYP3A4CYP2C19CYP2C9ALDH1A1
SCHEMBL16212885 0.83 TDP1 (0.50) CTSKCYP2C19ALDH1A1HIF1ASMN1; SMN2
SCHEMBL872678 0.83 KCNH2 (0.51) CTSKCYP3A4CYP2C19CYP2C9ALDH1A1
SCHEMBL28196662 0.83 CYP3A4 (0.45) CTSKCYP3A4CYP2C19CYP2C9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12603321-B2 Battery separators, electrodes, cells, lithium batteries and related methods CELGARD, LLC (US) 2026-04-14 US claimed
US-8383276-B2 High voltage electrolyte TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2013-02-26 US claimed
US-8288040-B2 High voltage electrolyte TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2012-10-16 US claimed
US-20110008680-A1 HIGH VOLTAGE ELECTROLYTE TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2011-01-13 US claimed
US-20100209780-A1 HIGH VOLTAGE ELECTROLYTE (Muldoon, Allred) TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2010-08-19 US claimed
US-20260149126-A1 POLYIMIDE COATED SEPARATORS, POROUS POLYIMIDE COATINGS, LITHIUM BATTERIES, AND RELATED METHODS CELGARD, LLC (US) 2026-05-28 US disclosed
US-12603321-B2 Battery separators, electrodes, cells, lithium batteries and related methods CELGARD, LLC (US) 2026-04-14 US disclosed
US-12555872-B2 Polyimide coated separators, porous polyimide coatings, lithium batteries, and related methods CELGARD, LLC 2026-02-17 US disclosed
US-20250316845-A1 COATED MICROPOROUS MEMBRANES, AND BATTERY SEPARATORS, BATTERIES, VEHICLES, AND DEVICES COMPRISING THE SAME CELGARD LLC (US) 2025-10-09 US disclosed
US-20250246760-A1 COATED MICROPOROUS MEMBRANES, AND BATTERY SEPARATORS, BATTERIES, VEHICLES, AND DEVICES COMPRISING THE SAME CELGARD LLC (US) 2025-07-31 US disclosed
US-20240329146-A1 IMPROVED BATTERIES, CELLS, COMPONENTS, AND TESTING THEREOF CELGARD, LLC 2024-10-03 US disclosed
US-20240313347-A1 IMPROVED BATTERY CELLS AND COMPONENTS THEREOF CELGARD, LLC 2024-09-19 US disclosed
EP-3535792-A1 BATTERY SEPARATORS Celgard, LLC (US) 2019-09-11 EP disclosed
US-8383276-B2 High voltage electrolyte TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2013-02-26 US disclosed
US-8288040-B2 High voltage electrolyte TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2012-10-16 US disclosed
US-20120183866-A1 Fluorinated Arylboron Oxalate as Anion Receptors and Additives for Non-Aqueous Battery Electrolytes Brookhaven Science Associates ,LLC (US) 2012-07-19 US disclosed
WO-2011031401-A2 LITHIUM NON-FLUORINATED AND FLUORINATED PHENYL TRIFLUORO BORATE SALTS FOR NON-AQUEOUS BATTERY ELECTROLYTES BROOKHAVEN SCIENCE ASSOCIATES LLC (US) 2011-03-17 WO disclosed
WO-2011014451-A2 FLUORINATED ARYLBORON OXALATE AS ANION RECEPTORS AND ADDITIVES FOR NON-AQUEOUS BATTERY ELECTROLYTES BROOKHAVEN SCIENCE ASSOCIATES LLC (US) 2011-02-03 WO disclosed
US-20110008680-A1 HIGH VOLTAGE ELECTROLYTE TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2011-01-13 US disclosed
US-20100209780-A1 HIGH VOLTAGE ELECTROLYTE (Muldoon, Allred) TOYOTA MOTOR ENGINEERING & MANUFACTURING NORTH AMERICA, INC. (US) 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12555872-B2 Polyimide coated separators, porous polyimide coatings, lithium batteries, and related methods DCX, GABRE, DYNC1I2 CTSK 3782/4885CYP3A4 4804/4885CYP2C19 4696/4885
US-12603321-B2 Battery separators, electrodes, cells, lithium batteries and related methods NES, LNPK, NEK9 CTSK 313/4885CYP3A4 4710/4885CYP2C19 4184/4885
US-20260149126-A1 POLYIMIDE COATED SEPARATORS, POROUS POLYIMIDE COATINGS, LITHIUM BATTERIES, AND RELATED METHODS GABRE, DCX, DYNC1I2 CTSK 3806/4885CYP3A4 4809/4885CYP2C19 4656/4885
US-20120183866-A1 Fluorinated Arylboron Oxalate as Anion Receptors and Additives for Non-Aqueous Battery Electrolytes SLCO2B1, SLCO1B1, SLCO4C1 CTSK 2685/4885CYP3A4 1186/4885CYP2C19 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.